Pipeline

As of April 25, 2022

State of New Product Development［PDF: 205.0 KB］

Disease Area:
  • * Asia:excluding Japan and China
Disease Area Development code Indications Stage
123Filed
 Region
Central nervous system
MP-214
Bipolar disorder
Filed
Asia
Generic name
Cariprazine
Category(Indications)
Dopamine D3/D2 receptor partial agonist(Bipolar disorder)
Origin/licensee
Licensed from Gedeon Richter (Hungary)
Central nervous system
MT-0551
Neuromyelitis optica spectrum disorder:NMOSD
Filed
Asia
Product name
Uplizna
Generic name
Inebilizumab
Category(Indications)
Humanized anti-CD19 monoclonal antibody(Neuromyelitis optica spectrum disorder:NMOSD)
Origin/licensee
Licensed from Horizon Therapeutics (Ireland)
Central nervous system
MT-0551
Myasthenia gravis
Phase3
Japan
Product name
Uplizna
Generic name
Inebilizumab
Category(Indications)
Humanized anti-CD19 monoclonal antibody(Myasthenia gravis)
Origin/licensee
Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
Central nervous system
MT-5199
Tardive dyskinesia
Filed
Asia
Product name
Dysval
Generic name
Valbenazine
Category(Indications)
Vesicular monoamine transporter type 2 inhibitor(Tardive dyskinesia)
Origin/licensee
Licensed from Neurocrine Biosciences (US)
Central nervous system
MT-1186
Amyotrophic lateral sclerosis: ALS / Oral suspension
Filed
US, Japan *
Generic name
Edaravone
Category(Indications)
Free radical scavenger(Amyotrophic lateral sclerosis: ALS / Oral suspension)
Origin/licensee
In-house　* NDA submission has been completed in the US, Japan, etc. and development stages for other countries are Phase 3.
Central nervous system
MT-210
Schizophrenia
Phase3
US,Europe
Generic name
Roluperidone
Category(Indications)
5-HT2A/Sigma 2 receptor antagonist(Schizophrenia)
Origin/licensee
Licensed to Minerva Neurosciences (US)
Central nervous system
ND0612
Parkinson's disease
Phase3
Global
Generic name
Levodopa/Carbidopa
Category(Indications)
Continuous SC pump(Parkinson's disease)
Origin/licensee
In-house
Central nervous system
MT-8554
Peripheral neuropathic pain
Phase2
Japan
Generic name
Elismetrep
Category(Indications)
TRPM8 antagonist(Peripheral neuropathic pain)
Origin/licensee
In-house
Central nervous system
MT-8554
Vasomotor symptoms associated with menopause
Phase2
Global
Generic name
Elismetrep
Category(Indications)
TRPM8 antagonist(Vasomotor symptoms associated with menopause)
Origin/licensee
In-house
Central nervous system
MT-3921
Spinal cord injury
Phase2
Global
Generic name
Unasnemab
Category(Indications)
Anti-RGMa antibody(Spinal cord injury)
Origin/licensee
Co-developed with Osaka University (Japan)
Immuno-inflammation
MT-5547
Osteoarthritis
Phase2/3
Japan
Generic name
Fasinumab
Category(Indications)
Fully human anti-NGF monoclonal antibody(Osteoarthritis)
Origin/licensee
Licensed from Regeneron(US)
Immuno-inflammation
MT-7117
Erythropoietic protoporphyria, X-Linked protoporphyria
Phase3
Global
Generic name
Dersimelagon
Category(Indications)
Selective melanocortin 1 receptor agonist(Erythropoietic protoporphyria, X-Linked protoporphyria)
Origin/licensee
In-house
Immuno-inflammation
MT-7117
Systemic sclerosis
Phase2
Global
Generic name
Dersimelagon
Category(Indications)
Selective melanocortin 1 receptor agonist(Systemic sclerosis)
Origin/licensee
In-house
Immuno-inflammation
MT-0551
IgG4-related disease
Phase3
Japan
Product name
Uplizna
Generic name
Inebilizumab
Category(Indications)
Humanized anti-CD19 monoclonal antibody(IgG4-related disease)
Origin/licensee
Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
Immuno-inflammation
MT-2990
Endometriosis
Phase2
Global
Category(Indications)
Fully human anti-interleukin-33 (IL-33) monoclonal antibody(Endometriosis)
Origin/licensee
In-house
Vaccines
MT-2355
Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants
Filed
Japan
Category(Indications)
Combined vaccine(Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)
Origin/licensee
Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
Vaccines
MT-2766
Prophylaxis of COVID-19
Phase3
Global *
Product name
Covifenz
Category(Indications)
Plant-derived VLP vaccine(Prophylaxis of COVID-19)
Origin/licensee
Medicago product (Canada)　* Regulatory approval has been obtained in Canada, and development stages for other countries are Phase 3.
Vaccines
MT-8972
Prophylaxis of H5N1 influenza
Phase2
Canada
Category(Indications)
Plant-derived VLP vaccine(Prophylaxis of H5N1 influenza)
Origin/licensee
Medicago product (Canada)
Vaccines
MT-7529
Prophylaxis of H7N9 influenza
Phase1
Category(Indications)
Plant-derived VLP vaccine(Prophylaxis of H7N9 influenza)
Origin/licensee
Medicago product (Canada)
Vaccines
MT-5625
Prophylaxis of rotavirus gastroenteritis
Phase1
Category(Indications)
Plant-derived VLP vaccine(Prophylaxis of rotavirus gastroenteritis)
Origin/licensee
Medicago product (Canada)
Vaccines
MT-2654
Prophylaxis of seasonal influenza/elderly
Phase1
Category(Indications)
Adjuvanted plant-derived VLP vaccine(Prophylaxis of seasonal influenza/elderly)
Origin/licensee
Medicago product (Canada)
Others
MP-513
Type 2 diabetes mellitus
Filed
Asia
Product name
Tenelia
Generic name
Teneligliptin
Category(Indications)
DPP-4 inhibitor(Type 2 diabetes mellitus)
Origin/licensee
In-house
Others
TA-7284
Chronic kidney disease with type 2 diabetes mellitus
Filed
Japan
Product name
Canaglu/INVOKANA
Generic name
Canagliflozin
Category(Indications)
SGLT2 inhibitor(Chronic kidney disease with type 2 diabetes mellitus)
Origin/licensee
In-house
Others
MT-6548
Renal anemia
Filed
Asia
Product name
Vafseo
Generic name
Vadadustat
Category(Indications)
Hypoxia-inducible factor prolyl hydroxylase inhibitor(Renal anemia)
Origin/licensee
Licensed from Akebia (US)
Others
MT-4580
Secondary Hyperparathyroidism
Phase3
China,Asia
Product name
Orkedia
Generic name
Evocalcet
Category(Indications)
Ca sensing receptor agonist(Secondary Hyperparathyroidism)
Origin/licensee
Licensed to Kyowa Kirin (Japan)
Others
MT-2765
Hypertension
Phase3
China
Category(Indications)
Renin inhibitor(Hypertension)
Origin/licensee
Licensed to Shanghai Pharmaceuticals (China)
Others
MT-8633/ TR1801-ADC
Solid tumor
Phase1
Category(Indications)
Anti-c-Met antibody drug conjugate(Solid tumor)
Origin/licensee
In-house / Collaborate with Open Innovation Partners (Japan)

There is no development status of the applicable area.

Please select one or more disease areas.

  • * Asia:excluding Japan and China
Development code Indications Previous Announcement As of Apr. 25, 2022
Stage
123FiledApproved
 Region Stage
123FiledApproved
 Region
MP-214
Bipolar disorder
Filed
Asia
Approved
Thailand
Generic name
Cariprazine
Category(Indications)
Dopamine D3/D2 receptor partial agonist(Bipolar disorder)
Origin/licensee
Licensed from Gedeon Richter (Hungary)
MT-5199
Tardive dyskinesia
Filed
Japan
Approved
Japan
Product name
Dysval
Generic name
Valbenazine
Category(Indications)
Vesicular monoamine transporter type 2 inhibitor(Tardive dyskinesia)
Origin/licensee
Licensed from Neurocrine Biosciences (US)
MT-2766
Prophylaxis of COVID-19
Filed
Canada
Approved
Canada *
Product name
Covifenz
Category(Indications)
Plant-derived VLP vaccine(Prophylaxis of COVID-19)
Origin/licensee
Medicago product (Canada)　* Regulatory approval has been obtained in Canada, and development stages for other countries are Phase 3.
MT-1186
Amyotrophic lateral sclerosis: ALS / Oral suspension
Filed
US
Filed
US, Japan **
Generic name
Edaravone
Category(Indications)
Free radical scavenger(Amyotrophic lateral sclerosis: ALS / Oral suspension)
Origin/licensee
In-house　** NDA submission has been completed in the US, Japan, etc. and development stages for other countries are Phase 3.
MT-2355
Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants
Phase3
Japan
Filed
Japan
Category(Indications)
Combined vaccine(Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)
Origin/licensee
Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)

This website uses cookies to provide better content. By browsing this site, you accept our use of cookies.
Privacy Policy